Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2016 - 2026)
Insight Molecular Diagnostics (IMDX) posted Return on Capital Employed of 213.69% for Q1 2026, down 13.76% sequentially from 187.84% in Q4 2025, and down 8055.0% YoY from 2.69% in Q1 2025.
Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2016 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported Return on Capital Employed for 11 years, with the latest figure at 213.69% in Q1 2026.
- Quarterly Return on Capital Employed fell 8055.0% year-over-year to 213.69% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 213.69% (down 8055.0% YoY) and the FY2025 annual result came in at 278.7%, down 15077.0% from the prior year.
- Return on Capital Employed slipped to 213.69% in Q1 2026 per IMDX's latest filing, from 187.84% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 11.13% in Q1 2023 and troughed at 213.69% in Q1 2026.
- A 5-year average of 71.68% and a median of 39.08% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed jumped 3627 bps in 2023, then tumbled 9485 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 15.43% in 2022, then sank by 68 bps to 25.95% in 2023, then sank by 315 bps to 107.72% in 2024, then tumbled by 74 bps to 187.84% in 2025, then declined by 14 bps to 213.69% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 213.69%, 187.84%, and 133.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 8.30% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 6.42% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -13.91% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 14.57% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 10.49% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 68.60% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 17.55% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 49.80% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 8.97% |
| 10 | Insight Molecular Diagnostics | 158.03 Mn | 139.50 Mn | 157,000.00 | -223.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -223.01% |
| Mar 31, 2026 | -253.29% |
| Dec 31, 2025 | -224.51% |
| Sep 30, 2025 | -154.97% |
| Jun 30, 2025 | -130.74% |
| Mar 31, 2025 | -154.83% |
| Dec 31, 2024 | -135.23% |
| Sep 30, 2024 | -69.29% |
| Jun 30, 2024 | -56.22% |
| Mar 31, 2024 | -62.31% |
| Dec 31, 2023 | -35.38% |
| Sep 30, 2023 | -26.92% |
| Jun 30, 2023 | -20.38% |
| Mar 31, 2023 | -11.13% |
| Dec 31, 2022 | -15.43% |
| Sep 30, 2022 | -27.79% |
| Jun 30, 2022 | -37.32% |
| Mar 31, 2022 | -47.40% |
| Dec 31, 2021 | -49.53% |
| Sep 30, 2021 | -28.09% |